News Headlines
-
CATUG And Crystal Bio Establish Strategic Partnership, Launching ‘CATUG-Crystal’ Joint Lab Dedicated To Advanced Nucleic Acid Analytical Services
2/22/2024
CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services.
-
Immunocore Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Evaluate IMC-F106C (PRAME HLA-A02) In Combination With Nivolumab In Its Registrational Phase 3 First-Line Advanced Cutaneous Melanoma Trial
2/22/2024
Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY) to investigate Immunocore’s ImmTAC bispecific TCR (T cell receptor) candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma.
-
AtomVie Global Radiopharma Collaborates With RLS & UPPI To Strengthen Its Existing U.S. Radiotherapeutic Distribution Network
2/22/2024
AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is proud to announce strategic collaborations with RLS Radiopharmacies and UPPI LLC.
-
AbbVie And Tentarix Announce Collaboration To Develop Conditionally-Active, Multi-Specific Biologics For Oncology And Immunology
2/22/2024
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.
-
Genezen Enters Licensing Agreement With CSL For The Cytegrity™ Stable Lentivirus Production System
2/21/2024
Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL.
-
Charles River And Wheeler Bio Complete Agreement To Accelerate The Journey From Discovery And CMC Development To Manufacturing
2/21/2024
Charles River Laboratories International, Inc. today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC (Chemistry, Manufacturing and Controls) platform.
-
CDMO Resilience Announces Significant Funding To Increase Aseptic Fill/Finish Manufacturing Capacity In Ohio And North Carolina Facilities
2/20/2024
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network. By scaling this capacity, Resilience aims to provide over 200 million units to its partners across its manufacturing network by 2025 in support of multiple modalities and therapeutic indications, including GLP-1.
-
Biocytogen And Gilead Enter Into A Multi-Target Antibody Collaboration Agreement
2/20/2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
-
Charles River Collaborates With Pluristyx, Expanding Its Portfolio Of Human Pluripotent Stem Cells
2/20/2024
Charles River Laboratories International, Inc. today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies.
-
Resilience Expands Clinical And Commercial Drug Product Manufacturing Capabilities And Capacities
2/20/2024
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network.